TMCnet News

Life Sciences Summit Will Showcase Immunomic Therapeutics
[October 31, 2016]

Life Sciences Summit Will Showcase Immunomic Therapeutics


On Wednesday, Nov. 2, Immunomic Therapeutics CEO, Dr. William Hearl will speak on Immuno-oncology and the future of personalized medicine. The panel will discuss immuno-oncology therapies applied to the most difficult to treat cancers including metastatic kidney cancer, metastatic melanoma, and lung cancer, among others. The panel will explore top-of-mind questions on immunotherapies including why all patients do not respond equally, or at all, and methods of predicting effective therapies for diverse cases.

Who: Dr. William Hearl, CEO, Immunomic Therapeutics

What: Panel discussion titled Immuno-Oncology: Cracking the Code of Personalized Medicine; open to conference attendees and media

When: Wednesday, Nov. 2, 1:15 pm EST

Where: 10 on the Park at Time Warner (News - Alert) Center, 60 Columbus Circle 10th Floor, New York, New York. Please enter at the West 60th St entrance for 60 Columbus Circle (between Equinox Gym and The Mandarin Oriental Hotel off Columbus Circle.) Bring photo ID.



About ITI

Immunomic Therapeutics, Inc. is a privately-held, clinical stage biotech company on a mission to pioneer vaccines that transform lives. The company, based in Rockville, MD, is developing nucleic acid vaccines based on the patented Lysosomal Associated Membrane Protein (LAMP) Technology. Termed LAMP-Vax™, the exclusive immunotherapy technology works with the body's natural biochemistry system and has the potential to improve a broad range of vaccines. ITI entered into a licensing agreement with Astellas Pharma Inc. in 2015 to explore the use of LAMP-Vax in the prevention and treatment of allergic diseases, and is now focused on cancer immunotherapy. The LAMP platform has been tested in Phase I and II clinical studies. For more information, please visit www.immunomix.com.



[ Back To TMCnet.com's Homepage ]